Results 181 to 190 of about 19,727 (209)

Sofosbuvir + simeprevir dominates sofosbuvir + ribavirin

PharmacoEconomics & Outcomes News, 2014
openaire   +1 more source

Ledipasvir/sofosbuvir/peginterferon/ribavirin/sofosbuvir

Reactions Weekly, 2016
openaire   +1 more source

Daclatasvir + sofosbuvir dominates sofosbuvir + ribavirin

PharmacoEconomics & Outcomes News, 2017
openaire   +1 more source

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

Lancet, The, 2014
Eric Lawitz, Mark S Sulkowski, Zobair M Younossi   +2 more
exaly  

Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study

Lancet, The, 2015
Chloe Orkin, Mark Nelson, Christoph J Stephan   +2 more
exaly  

Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection

New England Journal of Medicine, 2014
Nezam Afdhal, Paul Y Kwo, Massimo Puoti
exaly  

Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection

New England Journal of Medicine, 2013
Eric Lawitz, Alessandra Mangia, Mitchell N Davis   +2 more
exaly  

Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection

New England Journal of Medicine, 2014
Nezam Afdhal, K Rajender Reddy, David R Nelson   +2 more
exaly  

Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial

The Lancet Gastroenterology and Hepatology, 2018
Jason Grebely, Olav Dalgard, Evan B Cunningham   +2 more
exaly  

Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study

Life Sciences, 2020
Abdo A. Elfiky
exaly